This fungal–nanoparticle drug delivery platform uses Cryptococcus neoformans (CN) for effective drug delivery to the central nervous system (CNS). More than 1.2 billion people worldwide are affected by neurological disorders, yet fewer than 2% of approved therapeutics successfully enter the central nervous system (CNS) for meaningful therapeutic effects. Evidently, there is a significant unmet need for drug delivery to the CNS to counteract a plethora of maladies including neurodegenerative diseases (e.g., amyotrophic lateral sclerosis; ALS), brain cancers (e.g., Gliobastoma Multiforme; GBM), traumatic nervous system injury, and epilepsy.
Lou Gehrig’s disease (ALS) affects over 200,000 individuals globally and remains a fatal neurodegenerative condition with only marginally effective treatment options. Current ALS therapies are limited to small-molecule drugs that rely on passive diffusion to enter the CNS. Despite their ability to cross the blood-brain barrier (BBB), these agents suffer from poor CNS bioavailability due to rapid systemic distribution and off-target accumulation, resulting in modest clinical benefit and dose-limiting side effects. Additional challenges include the blood–spinal cord barrier and physicochemical properties (e.g., solubility, molecular weight, stability, etc.) that restrict drug accumulation at sites of motor neuron degeneration.
Glioblastoma (GBM) remains one of the most urgent and unmet needs in oncology. As the most aggressive primary brain tumor in adults, GBM is characterized by rapid growth, diffuse infiltration into surrounding brain tissue, and profound resistance to existing therapies. Despite decades of research, the standard of care—maximal surgical resection followed by radiation and chemotherapy with Temozolomide—offers only modest benefit, with median overall survival typically limited to 12–15 months and a five-year survival rate below 10%. The therapeutic challenge in GBM is driven by several factors: marked tumor heterogeneity, an immunosuppressive tumor microenvironment, and the protective Blood–brain barrier, which restricts effective drug delivery. In addition, GBM’s infiltrative nature prevents complete surgical removal and contributes to nearly universal recurrence. There is a critical need for innovative therapeutic strategies that go beyond cytotoxic approaches. Emerging modalities—including targeted therapies, immune-based treatments, gene and cell therapies, and advanced drug delivery systems—aim to overcome these barriers, improve tumor specificity, and generate durable responses. However, clinical success has been limited to date, underscoring the urgency for continued investment in novel mechanisms and translational research.
Researchers at the University of Florida have developed a fungal drug carrier platform for enhancing blood-brain barrier penetration and reducing off-target distribution. The platform exploits the natural immune evasiveness and CNS trafficking properties of an avirulent strain of Cryptococcus neoformans. The fungal carrier is surface-modified with drug-loaded nanoparticles, enabling immune-cell–mediated transport across the BBB and targeted delivery to the brain and spinal cord. The approach can significantly improve therapeutic efficacy, reduce dosing requirements, and minimize side effects. While initially developed for ALS, this platform is broadly applicable to a range of neurological and neurodegenerative disorders where effective CNS drug delivery remains a critical unmet need.
This fungal–nanoparticle delivery platform enables targeted transport of therapeutics across the blood–brain and blood–spinal cord barriers to improve CNS drug bioavailability and efficacy while minimizing off-target effects for the treatment of ALS and other neurological disorders
A fungal–nanoparticle drug delivery platform uses an avirulent strain of Cryptococcus neoformans to enable noninvasive transport of therapeutics across the blood–brain and blood–spinal cord barriers. Drug-loaded, FDA-approved nanoparticles are surface-conjugated to the fungal carrier, preserving payload stability while leveraging the organism’s naturally evolved immune-evasive and CNS-trafficking properties. Following systemic administration, the platform exploits immune-cell–mediated transport to cross CNS barriers and localize within brain and spinal cord tissues. Once in the CNS, the nanoparticles provide controlled and sustained drug release, increasing local therapeutic concentrations while minimizing systemic exposure and off-target effects. The modular design allows tuning of nanoparticle composition, drug payload, and release kinetics, enabling adaptation to multiple therapeutic agents and neurological indications while avoiding invasive CNS delivery methods.
